Source: Clinical Genetics. Unidade: FM
Subjects: HIPERPLASIA SUPRARRENAL CONGÊNITA, BIOLOGIA MOLECULAR, RASTREAMENTO, RECÉM-NASCIDO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVEIRA, E. L. et al. Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Clinical Genetics, v. 76, n. 6, p. 503-510, 2009Tradução . . Disponível em: https://doi.org/10.1111/j.1399-0004.2009.01274.x. Acesso em: 02 out. 2024.APA
Silveira, E. L., Elnecave, R. H., Santos, E. P. dos, Moura, V., Pinto, E. M., Nader, I. van der L., et al. (2009). Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Clinical Genetics, 76( 6), 503-510. doi:10.1111/j.1399-0004.2009.01274.xNLM
Silveira EL, Elnecave RH, Santos EP dos, Moura V, Pinto EM, Nader I van der L, Mendonca BB, Bachega TASS. Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia [Internet]. Clinical Genetics. 2009 ; 76( 6): 503-510.[citado 2024 out. 02 ] Available from: https://doi.org/10.1111/j.1399-0004.2009.01274.xVancouver
Silveira EL, Elnecave RH, Santos EP dos, Moura V, Pinto EM, Nader I van der L, Mendonca BB, Bachega TASS. Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia [Internet]. Clinical Genetics. 2009 ; 76( 6): 503-510.[citado 2024 out. 02 ] Available from: https://doi.org/10.1111/j.1399-0004.2009.01274.x
